Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: Levels of cholesterol and the cholesterol precursors desmosterol, lanosterol, 7DHC and its isomer 8-dehydrocholesterol (8DHC), in blood samples of 123 psychiatric patients on various antipsychotic and antidepressant drugs, and 85 healthy controls, are examined to see if observations in cell lines hold true for patients as well.
31 citations
TL;DR: This data indicates that high levels of stress and/or psychiatric diseases can play an important role in determining psoriasis, including the well‐known negative somato–psychiatric rebound that comes with the disease.
Abstract: Background It is known that stress and/or psychiatric diseases can play an important role in determining psoriasis, including the well-known negative somato–psychiatric rebound that comes with the disease.
Methods Samples of 38 subjects suffering from both moderate–severe psoriasis treated with anti-TNFα, and depressive and/or anxious mood disorders were studied. Part of them were additionally treated with escitalopram, whereas the other group only consulted to a dermatological and psychiatric follow-up.
The aim of this study was to determine if an improvement in the dermatological manifestation as well as an improvement in the anxious–depressive disorder can be observed.
Results The study revealed that patients treated with escitalopram had a reduction of psycho-diagnostic test scores that measure depression and anxiety levels as well as the values of pruritus.
Conclusion Our study suggests that psychological interventions and antidepressant medications may improve perceived symptom severity, quality of life and major compliance to the treatment in selected patients (suffering from psoriasis and mood disturbance), without a clinician necessarily being able to see an impact on psoriasis severity.
31 citations
TL;DR: The frequent attenders had a higher proportion of contacts for malignant disease, mental disorder, and gastrointestinal disease, and had a greater probability for a "superficial contact", were more likely to be referred to a specialist, were less likely to receive a psychotropic drug, and were morelikely to receive an antibiotic.
Abstract: To compare frequent with infrequent attenders at GPs' surgeries in a rural area in Slovenia with respect to morbidity, type of contact with the GP, referral pattern and the prescriptions given, a random sample of 623 records from a population-based register was analysed retrospectively. The frequent attenders had a higher proportion of contacts for malignant disease, mental disorder, and gastrointestinal disease. They also had a greater probability for a “superficial contact”, were more likely to be referred to a specialist, were less likely to receive a psychotropic drug, and were more likely to receive a prescription for an antibiotic. We conclude that there are differences in morbidity between the two groups. The high referring pattern and the high proportion of “superficial contacts” of the frequent attenders may reflect poor doctor/patient relationship of this group.
31 citations
TL;DR: P phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment in schizophrenic patients.
Abstract: This study examined the relationship between the metabolic ratios of dextromethorphan/dextrorphan, haloperidol disposition, and the incidence of extrapyramidal side effects in schizophrenic patients. Eighteen schizophrenic patients were phenotyped with a test dose of dextromethorphan prior to the initiation of haloperidol treatment. The metabolic ratio of dextromethorphan/dextrorphan was determined in each patient. Patients were treated with oral haloperidol 10 mg/day for 2 weeks. Blood samples for haloperidol and reduced haloperidol were obtained at week 2 of haloperidol treatment. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC with electrochemical detection. Significant correlations of dextromethorphan/dextrorphan metabolic ratios vs. plasma haloperidol concentrations, reduced haloperidol concentrations, and reduced haloperidol/haloperidol ratios were found (r = 0.726, P = 0.0007; r = 0.782, P = 0.0001; and r = 0.619, P = 0.006, respectively). Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 ± 1.42 [S.D.] ng/ml vs. 1.10 ± 0.46 ng/ml, P = 0.014 and 0.287 ± 0.102 vs. 0.192 ± 0.065, P = 0.030). The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 ± 2.91 ng/ml vs. 5.83 ± 1.79 ng/ml, P = 0.066 and 0.023 ± 0.017 vs. 0.011 ± 0.010, P = 0.077). Phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment. Further research with phenotyping and psychotropic drug metabolism in psychiatric patients is needed.
31 citations
Harvard University1, McLean Hospital2, Baylor College of Medicine3, University of Alabama at Birmingham4, University of York5, Columbia University Medical Center6, Martin Luther University of Halle-Wittenberg7, Marshfield Clinic8, Mayo Clinic9, Deaconess Hospital10, Montana State University11, Cold Spring Harbor Laboratory12, Hoffmann-La Roche13, University of California, San Diego14, New York University15
TL;DR: These results provide two independent proof-of-principle demonstrations of symptom relief by targeting a specific genotype and explicitly link an individual mutation to the pathophysiology of psychosis and treatment response.
31 citations